A G E N D A
CIBMTR WORKING COMMITTEE FOR MORBIDITY, RECOVERY AND SURVIVORSHIP WORKING COMMITTEE
Honolulu, HI
Saturday, February 15, 2025, 1:00 – 3:00 PM

Co-Chair:	**Hélène Schoemans, MD, PhD; University Hospitals Leuven and KU Leuven; Telephone: 321-634-6889; Email: helene.schoemans@uzleuven.be**
Co-Chair:	**Mohamed Sorror, MD, MSc; Fred Hutchinson Cancer Research Center; Phone: 206-667-6298; Email: msorror@fredhutch.org**
Co-Chair:	**Seth Rotz, MD; Cleveland Clinic, Cleveland, OH; Telephone: 216-442-8806; E-mail: rotzs@ccf.org**
Co-Chair:	**Sairah Ahmed, MD; University of Texas, MD Anderson Cancer Center, Houston, TX; Telephone: 713-794-5745; E-mail: sahmed3@mdanderson.org**
Scientific Director:	**Rachel Phelan, MD, MPH; CIBMTR® (Center for International Blood and Marrow Transplant Research), Milwaukee, WI; Telephone: 414-955-4610 E-mail: rphelan@mcw.edu**
Scientific Director:	**Amy Moskop, MD, MS; CIBMTR® (Center for International Blood and Marrow Transplant Research), Milwaukee, WI; Telephone: 414-805-0747 E-mail: amoskop@mcw.edu**
Statistical Director:	**Ruta Brazauskas, PhD; CIBMTR® (Center for International Blood and Marrow Transplant Research), Milwaukee, WI; Telephone: 414-456-8687; E-mail: ruta@mcw.edu**
Statistician:	**Andrew Peterson, MS; CIBMTR® (Center for International Blood and Marrow Transplant Research), Milwaukee, WI; Telephone: 414-805-8163; E-mail: andpeterson@mcw.edu**

---

1. **Introduction**
    a. Minutes from February 2024 (Attachment 1)

The CIBMTR Morbidity Recovery and Survivorship Working Committee (MRSWC) meeting was called to order at 1:00 HST on Friday, February 15, 2025 by Dr. Amy Moskop. She began by welcoming all the in-person and virtual attendees and providing the CIBMTR's Industry Funding Disclosure. Then, she introduced our committee's leadership, including Dr. Annie Im as our incoming chair, Dr. Michelle Schoettler as our Page Scholar, and Rebecca Higgins and Brandon Nuechterlein as our CAC representatives. After reviewing the committee's COI disclosures, she explained the sources of our HCT/CT data and their corresponding forms.

Dr. Michelle Schoettler then took over and explained some of the CIBMTR's resources, including PRO data, public datasets, and study summaries on our website. She then explained MRS committee membership, and that anyone that scanned their badge is now a member! Dr. Schoettler explained our goals of publishing high impact studies in a timely manner. As a Page scholar, she explained the program and her experience getting involved with CIBMTR. Lastly, she highlighted changes and additional restrictions with submitting proposals.

Dr. Seth Rotz introduced our studies' recent publications, as well as our current studies in progress. Please find them listed in sections 3 and 4.

Dr. Rachel Phelan introduced the scoring process for our 8 accepted proposals this year. Each presentation is about 5 minutes in length with about 5 minutes for questions. The proposals accepted to become studies boils down to their scientific impact, prioritization, and score. As these studies progress, those that are members of our working committee can contribute as authors, assuming substantial contributions to all steps of the study are made.

Dr. Mohamed Sorror and Dr. Sairah Ahmed then introduced the proposals listed in section 5. Please find their corresponding notes below.

2. **Accrual summary** (Attachment 2)

3. **Presentations, Publications or Submitted papers**
    a. **LE19-01d** Smith MA, Cheng G, Phelan R, Brazauskas R, Strom J, Ahn KW, Hamilton BK, Peterson A, Savani B, Schoemans H, Schoettler ML, Sorror M, Keller RL, Higham CS, Dvorak CC, Fineman JR, Zinter MS. Pulmonary hypertension in the intensive care unit after pediatric allogeneic hematopoietic stem cell transplant: Incidence, risk factors, and outcomes. ***Frontiers in Oncology. 14:1415984. doi:10.3389/fonc.2024.1415984. Epub 2024 May 29. PMC11167102.***
    b. **LE19-01c** Cheng G, Smith M, Phelan R, Brazauskas R, Strom J, Ahn KW, Hamilton B, Peterson A, Savani B, Schoemans H, Schoettler M, Sorror M, Higham C, Kharbanda S, Dvorak C, Zinter M. Epidemiology of diffuse alveolar hemorrhage in pediatric allogeneic hematopoietic cell transplant recipients. ***Transplantation and Cellular Therapy. 2024 Oct 1; 10(30):1017.e1-1017.e12. doi:10.1016/j.jtct.2024.07.022. Epub 2024 Jul 31.***
    c. **LE16-02b** Kahn J, Brazauskas R, Bo-Subait S, Buchbinder D, Hamilton BK, Schoemans H, Abraham AA, Agrawal V, Auletta JJ, Badawy SM, Beitinjaneh A, Bhatt NS, Broglie LA, Diaz M, Farhadfar N, Freytes CO, Gale RP, Ganguly S, Hayashi RJ, Hematti P, Hildebrandt GC, Inamoto Y, Kamble RT, Koo J, Lazarus HM, Mayo SJ, Mehta PA, Myers KC, Nishihori T, Prestidge T, Rotz SJ, Savani BN, Schears RM, Sharma A, Stenger E, Ustun C, Williams KM, Vrooman LM, Satwani P, Phelan R. Late effects after allogeneic hematopoietic cell transplantation in children and adolescents with non-malignant disorders: a retrospective cohort study. ***The Lancet. Child & Adolescent Health. doi:10.1016/S2352-4642(24)00167-6. Epub 2024 Aug 30.***
    d. **LE12-03a** Risk Factors for Solid Organ Graft Failure and Death in Hematopoietic Cell Transplant Recipients Undergoing Solid Organ Transplantation- A Retrospective Center for International Blood and Marrow Transplant Research (CIBMTR) and Organ Procurement & Transplantation Network Study. ***In Press.***
    e. **LE19-01c** Cheng G, Smith M, Phelan R, Brazauskas R, Strom J, Ahn KW, Hamilton B, Peterson A, Savani B, Schoemans H, Schoettler M, Sorror M, Higham C, Kharbanda S, Dvorak C, Zinter M. Epidemiology of diffuse alveolar hemorrhage in pediatric allogeneic hematopoietic cell transplant recipients. ***Transplantation and Cellular Therapy. 2024 Oct 1; 10(30):1017.e1-1017.e12. doi:10.1016/j.jtct.2024.07.022. Epub 2024 Jul 31.***
    f. **LE12-03b** Risk Factors for Solid Organ Graft Failure and Death in Solid Organ Transplant Recipients Undergoing Hematopoietic Cell Transplantation- A Retrospective Center for International Blood and Marrow Transplant Research (CIBMTR) and Organ Procurement & Transplantation Network (OPTN) Study. ***In Press.***
    g. **CT20-03a** New Comorbidity Index Predicts Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell Lymphoma. ***Submitted.***

h. **CT20-03b** Cytokine release syndrome and neurotoxicity following CD19-CAR T-cell therapy in aggressive B-cell lymphoma: a CIBMTR analysis. ***Submitted.***

4. Studies in progress (Attachment 3)

a. **AC16-01** Pattern of use and outcomes with donor lymphocyte infusion after human leukocyte antigen haploidentical allogeneic hematopoietic stem cell transplant (E Gupta/ J Foran/ V Roy). ***Manuscript Preparation***.
b. **LE17-01** Late effects after hematopoietic stem cell transplantation for sickle cell disease (E Stenger/ L Krishnamurti/ S Shenoy). ***Analysis.***
c. **LE18-01** Trends in late mortality amongst two year survivors of pediatric allogeneic hematopoietic cell transplantation for hematologic malignancies (Prakash Satwani/ Larisa Broglie). ***Manuscript Preparation.***
d. **CT19-02** Prolonged cytopenia following CD-19 targeted chimeric antigen receptor T therapy for diffuse large B-cell lymphoma (M Shadman). ***Manuscript Preparation.***
e. **LE19-02** Incidence and predictors of long-term toxicities and late side effects in elderly patients (>=50 years) receiving allogeneic hematopoietic cell transplantation for hematological malignancies (M Veeraputhiran/S Pingali/A Mukherjee/L Muffly). ***Analysis.***
f. **LE20-01** Cardiometabolic risk after total body irradiation during childhood (D Novetsky Friedman/E Chow). ***Manuscript preparation.***
g. **CT20-03c** Determinants of effectiveness of CAR T cells for lymphoma (H Hashmi/ R Shouval/ K Wudhikarn). ***Manuscript Preparation.***
h. **CT20-04** Determinants of outcomes after chimeric antigen receptor T cells for acute lymphoblastic leukemia (S Mirza/ D Ragoonanan). ***Data File Preparation.***
i. **LE21-01** Risk of subsequent neoplasms in patients with post-transplant cyclophosphamide use for graft-versus-host disease prophylaxis (A Tomas/I Muhsen/L Yanez San Segundo/S K. Hashmi/ M-Angel Perales/A Kansagra). ***Data File Preparation.***
j. **RT19-01** Analysis of comorbidity-associated toxicity at a regimen-based level (R Shouval/ B Savani/A Nagler). ***Analysis.***
k. **RT19-02** Hemorrhagic cystitis (HC) as a complication of hematopoietic cell transplantation with post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease prophylaxis compared to other allogeneic transplants (K Adekola/ N Ali/ O Frankfurt/ L Metheny/ J Moreira/ M de Lima). ***Protocol Development.***
l. **RT20-01** Toxicities of older adults receiving allogeneic hematopoietic cell transplant compared to younger patients (R Jayani/H Murff). ***Data File Preparation.***
m. **CT22-01** CD19-CAR-T therapy failure: Impact of subsequent therapy in patients with B-cell malignancies (L Gowda/ G Murthy). ***Protocol Development.***
n. **CT22-02** Machine learning for predicting toxicity and early clinical outcomes in DLBCL and B-ALL patients treated with commercial CAR T products in the real-world setting: an analysis of the CIBMTR registry (A Tomas/ L Appell/ E Bezerra/ A Mirza/ M Perales/ A Sharma/ Y Lin/ L Gowda/ G Murthy). ***Protocol Received.***
o. **MRS22-01** Racial/ethnic disparities and role of poverty in long-term health outcomes among survivors of allogeneic hematopoietic cell transplant performed in childhood (N Bhatt/A Sharma/L Jimenez-Kurlander/C Duncan). ***Protocol Development.***
p. **MRS22-02** Incidence, risk factors and outcomes of acute cardiac complications after post-transplant cyclophosphamide based GVHD prophylaxis: A retrospective analysis from the CIBMTR database (K Poonsombudlert/C Strouse/H Rangarajan/P Satwani/D Modi). ***Protocol Received.***
q. **CT23-01** Outcomes of CD19 CAR-T in patients who received lymphodepleting chemotherapy using fludarabine-containing versus other regimens (R Kamble/ N Ahmed/ S Ganguly/ A Sieg/ C

Strouse/ A Ali/ C Rodriguez-Bonilla/ K Nadiminti/ P Pophali/ S Mirza/ L Gowda). ***Manuscript Preparation.***

r. **MRS23-01** Updated Analysis of Long-Term Survival and Late Deaths after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies and Severe Aplastic Anemia (M Battiwalla/U Rao). ***Protocol Pending.***

s. **MRS24-01** Toxicity profile and survival of patients with body mass index >30 undergoing allogeneic stem cell transplantation (N Tijaro Ovalle/ A Jakubowski). ***Protocol Received.***

t. **MRS24-02** Determinants of immune effector cell-associated hematotoxicity following CAR-T therapy across disease entities (K Rejeski/ R Shouval). ***Protocol Received.***

5. Future/proposed studies

a. **PROP 2410-02** Association of fludarabine exposure on car-t outcomes (K Sweiss/ S Ahmed) (Attachment 4)

Dr. Karen Sweiss gave this presentation virtually. Since fludarabine exhibits wide PK variability after dosing, it leads to unpredictable dose-exposure (AUC) profiles. This study aims to assess the variability of AUC and model the outcomes for patients with MM or LBCL that have fludarabine.

The first question asked why ALL patients will not be included in this study. Dr. Sweiss said that MM and LBCL are good starting points, but ALL can be included. This echoes another comment to include a pediatric population.

The second comment addresses the variability of dosing based on product. It will be important to investigate this as a confounding factor.

Dr. Moskop mentioned that we only capture total dose and start date, not dosing on each day. The number of doses is not specified. Dr. Sweiss noted that they would still be able to run the model even without daily dosing data.

An additional comment asked that if this model becomes finalized, can this model become available through all centers associated with CIBMTR? Dr. Sweiss said that the next steps would be to validate the model with measured PK data. If the convergence is good, this may be used as a good dosing guide.

b. **PROP 2410-10/2410-232** Comparing the Toxicity Profile of AYA Patients vs Older Patients following anti-CD19 CAR T-cell Therapy for B-cell malignancies (I Sheikh/ P Kebriaei/ S Ahmed) (Attachment 5)

Dr. Irtiza Sheikh gave this presentation. This study aims to further our understanding of the impact of CAR-T cell toxicities in AYA patients with B-cell malignancies. This study includes LBCL and ALL patients.

The first question asked if LBCL includes primary mediastinal lymphoma. These patients are AYA and there is a confounding factor of the checkpoint inhibitors. They are not included for now but will gladly be considered.

The second question asked if we know disease burden and infection prior to infusion. Disease burden is captured on the forms. Infection pre-CAR T is captured only within the context of the comorbidity index.

The third comment mentions that there is some discrepancy in product. Also, they have enough patients to explore differences within the AYA group. Lastly, they are encouraged to explore the differences between patients treated in pediatric vs primarily adult hospitals.

c. **PROP 2410-14/2410-102/2410-124/2410-165** Impact of Baseline Co-Morbidities including HCT-CI and Renal Dysfunction on Non-Relapse Mortality and Survival in Myeloma Patients Treated with Chimeric Antigen Receptor T (CAR T) Cell Therapy and Developing a Co-Morbidity Score to Predict Outcomes (M Mohan/ C Schinke/ H Shaikh/ H Hashmi/ S Usmani/ M Janakiram/ G Kaur/ S Sidana/ D Hansen) (Attachment 6)

This presentation was given by Dr. Gurbakhash Kaur. The goal of this study is to create a validated risk prediction tool to assess the impact of comorbidities on treatment outcomes for CAR-T patients.

The first comment alluded to a presentation at ASH that created a CT-CI for patients with lymphoma. It is suggested to take this and if it works well with myeloma patients. Dr. Kaur mentioned that we would need to account for additional disease-specific details outside of comorbidities (which CT-CI is based on) so there remains value of creating a new score for these patients.

The second WC participant mentioned that NRM will likely be low and that ooking at overall survival as a primary endpoint may be better. Dr. Sorror agrees to look at OS and disease features. The HCT-CI does not translate as well to myeloma; CAR-T is more about relapse and relapse-related mortality.

The last comment it was that it would be interesting to include malnutrition, if available in the registry, as one of the comorbidities.

d. **PROP 2410-16/2410-154** CIBMTR Validation of the Transplant Conditioning Intensity (TCI) Classification System in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome receiving GVHD prophylaxis with or without Post-Transplant Cyclophosphamide (A Jimenez Jimenez/ B Shaffer/ C Jackson/ L Muffly) (Attachment 7)

This presentation was given by Dr. Clayton Jackson. The TCI score is a score developed by EBMT as a refinement to the classic RIC/MAC strata. Each regimen is assigned an intensity rate, and is used to calculate the score. This study hopes to validate the TCI score as a predictive measurement of conditioning intensity compared to RIC/MAC.

The first comment mentioned that we may not need to have our endpoints as long, since NRM has been improving throughout the years. Also, we may need to separate PTCy into a separate cohort.

Since this score was not originally data driven, the second comment suggested to not only validate the score, but to develop something better as well.

The third question addressed that era is a confounder in NRM. So when comparing the PTCy cohort, how do we know differences are due to the confounder or PTCy? Given that the dataset is large, it will be feasible to narrow something down to more in-line with the current era.

e. **PROP 2410-99/2410-260** Real World Experience of Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC HS) in CAR T-cell Recipients (K McNerney/ T Jain/ N Vojjala/ N Ahmed) (Attachment 8)

This presentation was given by Dr. Kevin McNerney. The goal of this study is to provide a descriptive analysis of IEC-HS, as well as a multivariate analysis to determine associated factors.

The first question asked how confident we are that all IEC-HS reported is accurate, and not severe CRS with MOD. Also, how confident that our registry identifies what was used to treat the HLH? Dr. Moskop added that HLH was previously captured within the context of CRS (child question) but has since been separated from CRS so ideally we are capturing these patients better. However, past data will likely not be clean. Additionally, organ toxicity collection is very limited within the registry so will likely not be useful for IEC-HS grading purposes.

There are dates for resolution of IEC-HS collected. Also, there are grade 3 organ toxicities and peak ferritin collected to help with diagnosis. For the treatments, there is a field that asks for the specific HLH treatment, separate from CRS data collected.

The second comment said that these numbers are likely underreported. We may need to come up with our own criteria to define this outside of the ASTCT consensus criteria.

f. **PROP 2410-248** Impact of Li Fraumeni syndrome upon outcomes of Hematopoietic stem cell transplant recipients of hematologic malignancies (K Singh Sandhu/ R Nakamura) (Attachment 9)

Dr. Karamjeet S Sandhu gave this presentation. Li-Fraumeni syndrome is an autosomal dominant disorder characterized by a germline TP53 mutation, and about 4% of these patients will go on to develop hematologic malignancies. This study aims to evaluate EFS and other outcomes in this cohort.

The first comment from the audience brings up that the primary endpoint is at 4 years, but about 25% of the population won't have 4-year follow-up. It is agreed that by the time we would run the analysis, the data may mature some more.

The second question asked if we have samples for these patients in the repository. We do not know the number currently, but it is a number that we would be able to pull.

g. **PROP 2410-249** Clonal Cytopenia Mutations: The Impact of the Recipient's Underlying Malignant Disease Biology on Posttransplant Engraftment of Donor-derived Clonal Cytopenia (CH) Clones (M Kulasekaran/ G Hildebrandt) (Attachment 10)

This presentation was given by Dr. Monika Kulasekaran. The goal of this study is to evaluate the impact of disease biology in the engraftment of donor CH clones in select diseases, perform a comparative analysis of pre-HCT bone marrow molecular profiling, and post-HCT molecular testing to identify the acquisition of novel mutations.

The first comment addresses that CHIP mutations are driven by age. Therefore, it may make sense to restrict it to older donor-recipient pairs.

The second question asked if we would collect samples randomly and evaluate? The PIs will restrict by donor age (40+ years) and then would test the donor samples randomly. There is no plan to test the recipient samples.

The third comment mentions that we will need to look at the data closely and make sure we have all of the donors that we need as samples. It was suggested to look at available specimens on the BMT CTN public website for post-HCT sample availability

h. **PROP 2410-258** The Risk of Engraftment Syndrome in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: A Comparison of Plerixafor + G-CSF vs. G-CSF Alone (N Tiwari/ J Holter Chakrabarty/ P Vallabhaneni) (Attachment 11)

This presentation was given by Dr. Nishant Tiwari. The goal of this study is to study the association of incidence of ES in patients receiving ASCT for MM who were treated with Plerixafor + G-CSF vs. G-CSF alone.

A question was asked if we should shorten the time-period of data collected. Over time, their cell populations that are mobilized may begin to differ. This is definitely something that can be looked into.

Proposed studies; not accepted for consideration at this time

i. **PROP 2407-03** Assessing the Risk of Secondary Breast Cancer Malignancy in Survivors Following Radiation Therapy Post- pediatric bone marrow Transplantation (BMT) (M Gabriel/ I Twist). ***Dropped due to small sample size.***
j. **PROP 2408-11** Endocrine impairments after hematopoietic stem cell transplantation based on the big database, CIBMTR (M Pamukcuoglu). ***Dropped due to overlap with current study/publication.***
k. **PROP 2408-12** Which Treatment is Best for Hematopoietic Stem Cell Transplantation Associated Thrombotic Microangiopathy? (M Pamukcuoglu). ***Dropped due to low scientific impact.***
l. **PROP 2409-03** CRS-related and driving-related restriction durations following BCMA CAR-T therapy (R Banerjee). ***Dropped due to overlap with current study/publication.***
m. **PROP 2409-10** Incidence, Causes and Outcome of End Stage Renal Disease Post-Allogeneic HSCT (F Andreozzi/ G Gambino). ***Dropped due to supplemental data needed.***
n. **PROP 2409-24** Late effects in allogeneic HCT patients receiving post-transplant cyclophosphamide for hematological malignancies. (P Munshi/ N Hossain). ***Dropped due to overlap with current study/publication.***
o. **PROP 2409-28** Identifying Patients Who Derive Survival Benefits from Reduced Intensity Conditioning Regimen (Y Akahoshi/ J Levine). ***Dropped due to overlap with current study/publication.***

p. **PROP 2409-34** Molecular origin of second primary malignancy after CAR19 therapy for B-cell lymphoma. (D Miklos/ M Hamilton). ***Dropped due to overlap with current study/publication***
q. **PROP 2410-20** What is the risk of subsequent neoplasm in the modern era of hematopoietic cell transplantation? (O Ringden/ B Sadeghi). ***Dropped due to overlap with current study/publication***
r. **PROP 2410-39** Safety and Effectiveness of CAR-T Cell Therapy in Patients with B-Cell Malignancies and Heart Failure (G Sanchez-Petitto/ P Strati). ***Dropped due to supplemental data needed.***
s. **PROP 2410-48** Outcomes of Grade 3 & 4 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in patients who receive CD-19 - directed CAR-T cell therapy for Large B-Cell Lymphoma (LBCL) (A Gradone/ U Gergis). ***Dropped due to overlap with current study/publication.***
t. **PROP 2410-49** Outcomes of Grade 3 and 4 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in patients who receive BCMA -directed CAR-T cell therapy for Multiple Myeloma (A Gradone/ U Gergis). ***Dropped due to overlap with current study/publication.***
u. **PROP 2410-51** Patient Reported Outcomes of Grade 3 & 4 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in patients who receive CAR-T cell therapy for hematologic malignancies (A Gradone/ U Gergis). ***Dropped due to small sample size.***
v. **PROP 2410-59** Evaluation of the Incidence of Pregnancy and Outcomes Post CAR-T Cell Therapy (S Raghunandan/ V Bachanova). ***Dropped due to small sample size.***
w. **PROP 2410-92** Safety and Efficacy of CAR-T in Multiple Myeloma Patients with Pre-existing Heart Failure (H Shaikh/ Y Efebera). ***Dropped due to supplemental data needed.***
x. **PROP 2410-95** Second Primary Malignancies in Patients with Relapsed/Refractory Multiple Myeloma after Commercial BCMA-directed CAR T-cell therapy (D Dima/ D Hansen). ***Dropped due to overlap with current study/publication.***
y. **PROP 2410-96** Real world data for lifileucel (J Wagner). ***Dropped due to small sample size.***
z. **PROP 2410-104** Neurologic and Cognitive Health of Survivors of Chimeric Antigen Receptor Therapy in the United States. (V Irizarry Gatell/ R Faramand). ***Dropped due to small sample size.***
aa. **PROP 2410-109** Post-transplant toxicity and non-relapse mortality in recipients of low-intensity therapies before allogeneic stem cell transplant. (L Gowda/ K Chetlapalli). ***Dropped due to small sample size.***
bb. **PROP 2410-118** Incidence and risk factors for therapy-associated myeloid neoplasms following chimeric antigen receptor T-cell therapy (R Stubbins/ H Cherniawsky). ***Dropped due to overlap with current study/publication.***
cc. **PROP 2410-119** Incidence of secondary malignancies following commercial chimeric antigen receptor T-cell (CAR-T) therapy. (B Gattas/ U Gergis). ***Dropped due to overlap with current study/publication.***
dd. **PROP 2410-122** Pulmonary function testing to predict the risk of complications after CAR-T therapies in hematologic malignancies (A Sheshadri/ S Ahmed). ***Dropped due to supplemental data needed.***
ee. **PROP 2410-129** The Cardiac Toll of CART-T Therapy: Long-Term Implications (D Jamil/ S Farhan/ M Reddy). ***Dropped due to supplemental data needed.***
ff. **PROP 2410-142** Treatment related mortality according to post infusion time in recipients of FDA approved BCMA and CD 19 CART therapy (N Vojjala/ N Ahmed). ***Dropped due to low scientific impact.***
gg. **PROP 2410-146** An assessment of conditioning dose intensity dosing in the setting of post-transplant cyclophosphamide (PTCy) (T Wang/ A Jimenez Jimenez). ***Dropped due to overlap with current study/publication.***

hh. **PROP 2410-173** Understanding updates to prognosis as complications accumulate in pediatric stem cell transplantation (J O'Brien/ G Chain/ E Fraint). ***Dropped due to overlap with current study/publication.***

ii. **PROP 2410-183** Real-world experience of Second Primary Malignancies post treatment with CAR-T cell therapy in patients with Multiple Myeloma, ALL, Lymphoma (N Vojjala/ N Ahmed). ***Dropped due to overlap with current study/publication.***

jj. **PROP 2410-188** Impact of Pre-treatment Liver-related Factors on Clinical Outcomes after CAR T-cell Therapy for Lymphoma. (S Ahmed/ A Lionel). ***Dropped due to supplemental data needed.***

kk. **PROP 2410-196** Health-Related Quality of Life (HRQoL) Following Chimeric Antigen Receptor T-Cell Therapy for Hematological Malignancies. (N Abdallah/ S Gupta). ***Dropped due to small sample size.***

ll. **PROP 2410-209** Incidence and Treatment of Movement and Neuro-cognitive treatment emergent adverse events (MNTs) following BCMA CAR-T cell therapy in patients with multiple myeloma. (N Vojjala/ N Ahmed). ***Dropped due to supplemental data needed***

mm. **PROP 2410-240** Role of baseline inflammatory markers in toxicities and outcomes post CD19 CAR-T cell therapy in lymphoma (M Junaid Tariq). ***Dropped due to overlap with current study/publication.***

6. Other business

a. Update on Female-Specific Systematic Review

Dr. Phelan closed out to give an update on our Female-Specific Systematic Review. Also, a big thank you to Dr. Mohamed Sorror and Dr. Hélène Schoemans for serving on our committee as chairs! Lastly, thank you to everyone for joining in person or virtually!

Working Committee Overview Plan for 2025-2026

Study number and title	Current status	Chairs priority
AC16-01: Pattern of use and outcomes with donor lymphocyte infusion after human leukocyte antigen haploidentical allogeneic hematopoietic stem cell transplant.	Manuscript preparation	3
LE17-01: Late effects after hematopoietic stem cell transplantation for sickle cell disease.	Analysis	1
LE18-01: Trends in late mortality amongst two-year survivors of pediatric allogeneic hematopoietic cell transplantation for hematologic malignancies	Manuscript preparation	1
CT19-02: Prolonged cytopenia following CD-19 targeted chimeric antigen receptor T therapy for diffuse large B-cell lymphoma.	Manuscript preparation	1
LE19-02: Incidence and predictors of long-term toxicities and late side effects in elderly patients (≥60 years) receiving allogeneic hematopoietic cell transplantation for hematological malignancies	Analysis	2
LE20-01: Cardiometabolic risk after total body irradiation during childhood	Manuscript preparation	2

CT20-03a: New Comorbidity Index Predicts Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell Lymphoma	Submitted	1
CT20-03b: Cytokine release syndrome and neurotoxicity following CD19-CAR T-cell therapy in aggressive B-cell lymphoma: a CIBMTR analysis	Manuscript preparation	1
CT20-03c: Determinants of effectiveness of CAR T cells for lymphoma	Manuscript preparation	1
LE21-01: Risk of subsequent neoplasms in patients with post-transplant cyclophosphamide use for graft-versus-host disease prophylaxis	Data file preparation	2
RT19-01: Analysis of comorbidity-associated toxicity at a regimen-based level	Manuscript prep	1
RT19-02: Hemorrhagic cystitis as a complication of hematopoietic stem cell transplantation in the post-transplant cyclophosphamide graft-versus-host disease prophylaxis era compared to other allogeneic stem cell transplants	Data file preparation	1
RT20-01: Toxicities of older adults receiving allogeneic hematopoietic cell transplant compared to younger patients	Analysis	1
CT22-01: CD19-CAR-T therapy failure: Impact of subsequent therapy in patients with B-cell malignancies	Protocol development	2
CT22-02: Machine learning for predicting toxicity and early clinical outcomes in DLBCL and B-ALL patients treated with commercial CAR T products in the real-world setting: an analysis of the CIBMTR registry	Protocol development	2
MRS22-01: Racial/ethnic disparities and role of poverty in long-term health outcomes among survivors of allogeneic hematopoietic cell transplant performed in childhood	Protocol development	2
MRS22-02: Post-transplant cyclophosphamide related cardiomyopathy; incidence, risk factors and outcome: A retrospective review from CIBMTR database	Protocol development	3
CT23-01: Outcomes of CD19 CAR-T in patients who received lymphodepleting chemotherapy using fludarabine-containing versus other regimens	Manuscript preparation	1
MRS23-01: Updated Analysis of Long-Term Survival and Late Deaths after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies and Severe Aplastic Anemia	Protocol pending	3
MRS24-01: Toxicity profile and survival of patients with BMI >30 undergoing allogeneic stem cell transplantation	Protocol received	3
MRS24-02: Determinants of immune effector cell-associated hematotoxicity (ICAHT) following CAR-T therapy across disease entities	Protocol development	2